Organon (OGN) said Tuesday it acquired from Biogen (BIIB) the regulatory and commercial rights to Tofidence for intravenous infusion in the US.
Tofidence, a biosimilar to Actemra, is indicated for the treatment of arthritis and COVID-19, Organon said.
The company said the deal includes an upfront payment to Biogen, with Organon assuming the obligation to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments that Biogen owes to Bio-Thera Solutions, the product developer.
Organon said Bio-Thera Solutions will keep manufacturing rights for Tofidence in the US.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.